세계의 구조적 심질환용 기기 시장 : 수기별, 제품별, 최종 사용자별, 지역별 예측(-2029년)

The global Structural heart devices market is projected to reach USD 25.69 billion by 2029 from USD 16.31 billion in 2024, at a CAGR of 9.5% from 2024 to 2029. Drivers of growth in the market for structural heart devices include mounting incidence rates of valvular and congenital heart diseases, high advancement rates of minimally invasive technologies such as TAVR and TMVR, and rising adoption rates since global populations are aging and healthcare infrastructure is being enhanced.

"By product segment Heart Valve segment to account for the largest share during the forecast period"

The most paramount segment of the structural heart devices market is heart valves primarily due to the higher prevalence of valvular diseases such as aortic stenosis and mitral regurgitation, especially in the geriatric population. These have treatment requirements at the earlier stages, with the latest breakthroughs in minimally invasive techniques being TAVR and TMVR, which have drastically altered the approach to treating these diseases. The above techniques offer reduced recovery times, fewer surgical risks, and greater access to patients classified as high-risk or inoperable when compared to traditional open-heart surgery.

Technological upgrades, for example, next-generation valves with improved durability, better sealing, and optimized delivery mechanisms form one of this segment's most important demand drivers. Edwards Lifesciences, Medtronic, and Abbott companies are heavily investing in developing advanced transcatheter heart valves, thus further strengthening the dominancy of the segment. In addition, the growing adoption of these products in developed and emerging markets, supported by growth in reimbursement policies and demonstrated clinical success rates, further solidifies the heart valve segment as the largest and fastest-growing category in the structural heart market.

"APAC is estimated to register the highest CAGR during the forecast period."

The Structural heart devices market is divided into Five regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region witnessed the highest CAGR during the forecast period. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. The increasing diabetic population and increase in obesity due to sedentary lifestyles are also driving the growth of Structural heart devices in the APAC region.

The breakdown of the profile of primary participants in the Structural heart devices market:

• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%, Middle East & Africa-5%

List of Companies Profiled in the Report

• Boston Scientific Corporation (U.S)
• Edwards Lifesciences Corporation (U.S)
• Medtronic (Ireland)
• Boston Scientific Corporation (U.S
• Abbott (U.S)
• Teleflex (U.S)
• Integer Holdings Corporation (U.S)
• Lepu Medical Technology Co.Ltd.(China)
• TTK (India)
• Artivion, Inc. (U.S)
• Venus Medtech, Inc. (China)
• Cook (U.S)
• SMT (India)
• Meril Lifesciences Pvt.Ltd (India)
• W.L Gore & Associates, Inc. (U.S)
• Cordis (U.S)
• Foldax (U.S)
• Micro Interventional Devices, Incorporated (U.S)
• Cardiac Dimensions (U.S)
• HighLife Medical (France)
• Mitralign (U.S)
• Braile Biomedica (Brazil)
• JenaValve (Germany)
• Corcym (Italy)
• Xeltis (Switzerland)
• Innovheart SRL (U.S)

Research Coverage

This report studies the Structural heart devices market based on product, procedure, end users and region. It also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates the market's opportunities and challenges for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total Structural heart devices market. The report forecasts the revenue of the market segments to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (technological advancements), restraints (Cost of the system), challenges (regulatory policies), and opportunities (Increase in minimally invasive procedures) contributing to the growth of the Structural heart devices market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Structural heart devices market.
• Market Development: Comprehensive information on the lucrative emerging markets type and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, and investments in the Structural heart devices market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Structural heart devices market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.2.2 TOP-DOWN APPROACH
  • 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 DEMAND-SIDE ANALYSIS
• 2.3 GROWTH FORECAST
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 STRUCTURAL HEART DEVICES MARKET OVERVIEW
• 4.2 NORTH AMERICA: STRUCTURAL HEART DEVICES MARKET, BY PRODUCT AND COUNTRY
• 4.3 STRUCTURAL HEART DEVICES MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing geriatric population
    • 5.2.1.2 Increasing preference for minimally invasive surgeries
    • 5.2.1.3 Rising awareness about structural heart diseases
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of devices and limited reimbursement
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emergence of tissue-engineered heart valves
    • 5.2.3.2 Expanding healthcare facilities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory and approval challenges
    • 5.2.4.2 Intense competition among market players
    • 5.2.4.3 Lack of skilled professionals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 MINIMALLY INVASIVE PROCEDURES
  • 5.3.2 TECHNOLOGICAL ADVANCEMENTS IN DEVICE DESIGN
  • 5.3.3 AI AND MACHINE LEARNING INTEGRATION
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5.2 AVERAGE SELLING PRICE, BY KEY PLAYER
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Transcatheter aortic valve replacement
    • 5.10.1.2 Transcatheter mitral aortic valve replacement
  • 5.10.2 COMPLEMENTARY TECHNOLOGIES
    • 5.10.2.1 3D printing
• 5.11 PATENT ANALYSIS
• 5.12 TRADE ANALYSIS
  • 5.12.1 HS CODES
  • 5.12.2 EXPORT DATA
  • 5.12.3 IMPORT DATA
• 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 SAPIEN 3 TRANSCATHETER HEART VALVE FOR PRECISION PLACEMENT
  • 5.14.2 MITRACLIP TRANSCATHETER EDGE-TO-EDGE REPAIR TO REDUCE HOSPITALIZATION
  • 5.14.3 WATCHMAN FLX DEVICE FOR LEFT ATRIAL APPENDAGE
• 5.15 REGULATORY LANDSCAPE
  • 5.15.1 REGULATORY ANALYSIS
    • 5.15.1.1 North America
      • 5.15.1.1.1 US
      • 5.15.1.1.2 Canada
    • 5.15.1.2 Europe
    • 5.15.1.3 Asia Pacific
      • 5.15.1.3.1 Japan
      • 5.15.1.3.2 China
  • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.16 PORTER'S FIVE FORCE ANALYSIS
  • 5.16.1 THREAT OF NEW ENTRANTS
  • 5.16.2 THREAT OF SUBSTITUTES
  • 5.16.3 BARGAINING POWER OF SUPPLIERS
  • 5.16.4 BARGAINING POWER OF BUYERS
  • 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS
  • 5.17.2 BUYING CRITERIA
• 5.18 REIMBURSEMENT ANALYSIS
• 5.19 UNMET NEEDS AND END-USER EXPECTATIONS
  • 5.19.1 UNMET NEEDS
  • 5.19.2 END-USER EXPECTATIONS
• 5.20 IMPACT OF AI/GEN AI ON STRUCTURAL HEART DEVICES MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY COMPANIES IMPLEMENTING AI
  • 5.20.3 MARKET POTENTIAL OF AI IN STRUCTURAL HEART DEVICES MARKET

6 STRUCTURAL HEART DEVICES MARKET, BY PROCEDURE

• 6.1 INTRODUCTION
• 6.2 REPLACEMENT PROCEDURES
  • 6.2.1 TAVR/TAVI REPLACEMENT PROCEDURES
    • 6.2.1.1 Quicker recuperation and shorter hospital stays to promote growth
  • 6.2.2 SAVR PROCEDURES
    • 6.2.2.1 Wide adoption for treating valvular heart diseases to sustain growth
• 6.3 REPAIR PROCEDURES
  • 6.3.1 CLOSURE PROCEDURES
    • 6.3.1.1 Increasing prevalence of structural heart defects to boost market
  • 6.3.2 ANNULOPLASTY
    • 6.3.2.1 Growing focus on safety and efficacy to drive market
  • 6.3.3 VALVULOPLASTY
    • 6.3.3.1 Increasing cases of aortic stenosis and valvular regurgitation to fuel market
  • 6.3.4 TMVR PROCEDURES
    • 6.3.4.1 Growing preference over valve replacement to promote growth
  • 6.3.5 TEER PROCEDURES
    • 6.3.5.1 Global prevalence of mitral regurgitation to expedite growth

7 STRUCTURAL HEART DEVICES MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 HEART VALVE DEVICES
  • 7.2.1 TRANSCATHETER HEART VALVES
    • 7.2.1.1 Transcatheter mitral valve replacement
      • 7.2.1.1.1 Growing use in treating age-related degeneration and heart diseases to boost market
    • 7.2.1.2 Transcatheter aortic valve replacement
      • 7.2.1.2.1 Increasing instances of aortic valve replacement to aid growth
  • 7.2.2 SURGICAL VALVES
    • 7.2.2.1 Mechanical valves
      • 7.2.2.1.1 Higher durability and affordability to encourage growth
    • 7.2.2.2 Biological valves
      • 7.2.2.2.1 Need for reduced incidence of bleeding to accelerate growth
• 7.3 OCCLUDERS, CLOSURE SYSTEMS, AND DELIVERY SYSTEMS
• 7.4 ANNULOPLASTY RINGS
  • 7.4.1 HIGH PREVALENCE OF MITRAL AND TRICUSPID VALVE REGURGITATION DISEASES TO PROMOTE GROWTH
• 7.5 ACCESSORIES
  • 7.5.1 CATHETERS
    • 7.5.1.1 Growing preference for minimally invasive procedures to fuel market
  • 7.5.2 GUIDEWIRES
    • 7.5.2.1 Need for precise navigation and placement of medical devices to augment growth
  • 7.5.3 SHEATHS
    • 7.5.3.1 Need for minimizing vascular trauma to promote growth
  • 7.5.4 OTHER ACCESSORIES

8 STRUCTURAL HEART DEVICES MARKET, BY END USER

• 8.1 INTRODUCTION
  • 8.1.1 HOSPITALS
    • 8.1.1.1 Ability to handle large volume of patients to boost market
  • 8.1.2 AMBULATORY SURGICAL CENTRES
    • 8.1.2.1 Faster procedure time and lower infection rates to drive market
  • 8.1.3 OTHER END USERS

9 STRUCTURAL HEART DEVICES MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Favorable reimbursement scenario to augment growth
  • 9.2.3 CANADA
    • 9.2.3.1 Rising prevalence of target diseases to drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Increase in geriatric and obese population to stimulate growth
  • 9.3.3 UK
    • 9.3.3.1 Increasing incidence of peripheral vascular diseases to support growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Favorable government initiatives to drive market
  • 9.3.5 ITALY
    • 9.3.5.1 Increasing health expenditure and rising diabetes prevalence to boost market
  • 9.3.6 SPAIN
    • 9.3.6.1 Growing geriatric population to propel market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 JAPAN
    • 9.4.2.1 Increasing healthcare expenditure to boost market
  • 9.4.3 CHINA
    • 9.4.3.1 Growing target patient population to drive market
  • 9.4.4 INDIA
    • 9.4.4.1 Increasing prevalence of diabetes to expedite growth
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Growing hospitalizations due to coronary artery diseases to fuel market
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Increasing prevalence of hypertension to support growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Rising healthcare expenditure to aid growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Increasing prevalence of cardiovascular diseases to spur growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Rising cases of hypertension and associated cardiovascular diseases to drive market
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 10.3 REVENUE ANALYSIS, 2019-2023
• 10.4 MARKET SHARE ANALYSIS, 2023
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Product footprint
    • 10.5.5.3 Procedure footprint
    • 10.5.5.4 End-user footprint
    • 10.5.5.5 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 DYNAMIC COMPANIES
  • 10.6.3 RESPONSIVE COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 10.7 BRAND/PRODUCT COMPARISON
• 10.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.8.1 FINANCIAL METRICS
  • 10.8.2 COMPANY VALUATION
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 10.9.2 DEALS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 EDWARDS LIFESCIENCES CORPORATION
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 MEDTRONIC
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches and approvals
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 ABBOTT
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches and approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 BOSTON SCIENTIFIC CORPORATION
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches and approvals
  • 11.1.5 TELEFLEX
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches and approvals
      • 11.1.5.3.2 Deals
  • 11.1.6 INTEGER HOLDINGS CORPORATION
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
  • 11.1.7 LEPU MEDICAL TECHNOLOGY CO., LTD.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches and approvals
  • 11.1.8 TTK HEALTHCARE
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
  • 11.1.9 ARTIVION, INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 VENUS MEDTECH (HANGZHOU) INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Product launches and approvals
  • 11.1.11 LIFETECH SCIENTIFIC CORPORATION
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
  • 11.1.12 COOK
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Deals
  • 11.1.13 CORDIS
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches and approvals
  • 11.1.14 SMT
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Other developments
  • 11.1.15 MERIL LIFE SCIENCES PVT. LTD.
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
  • 11.1.16 W. L. GORE & ASSOCIATES, INC.
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 FOLDAX
  • 11.2.2 MICRO INTERVENTIONAL DEVICES, INCORPORATED
  • 11.2.3 CARDIAC DIMENSIONS
  • 11.2.4 BIOTRONIK
  • 11.2.5 HIGHLIFE MEDICAL
  • 11.2.6 MITRALIGN
  • 11.2.7 BRAILE BIOMEDICA
  • 11.2.8 JENAVALVE
  • 11.2.9 CORCYM
  • 11.2.10 XELTIS
  • 11.2.11 INNOVHEART SRL

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS